Antipsychotic Drugs: Technologies and Global Markets

This report provides a detailed description of the market for antipsychotic drugs. The report highlights the current and future market potential of antipsychotic drugs and provides a detailed analysis of the competitive environment, regulatory scenario, technological advancements, patent analysis, pipeline analysis, drivers, restraints, opportunities and trends in the market. The report also covers market projections through 2023, as well as market shares for key market players. The report segments the market for antipsychotic drugs based on the mechanism of action, disease indication and geography.

Based on the mechanism of action, the market is segmented into D2 antagonists, D2/5HT2A antagonists and D2 partial agonists. The market size includes both branded and generic drugs. Based on disease indication, the market is segmented into schizophrenia, bipolar disorder, major depressive disorder (MDD), and other diseases including anxiety, autism and dementia. By geography, the market has been segmented into the North America, Europe, Asia-Pacific, South America, and Middle East and Africa regions. The North America region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., France, Italy, Spain and the rest of Europe. Asia-Pacific includes China, India, Japan and the rest of Asia-Pacific. For market estimates, data has been provided for 2017 as the base year, with forecasts for 2018 through 2023.

The Report Includes:

22 data tables and 36 additional tables
An overview of the global market for antipsychotic drugs
Analyses of global market trends, with data from 2017, estimates for 2018 and projections of CAGRs through 2023
Country specific data and analysis for United States, Canada, Mexico, UK, France, Germany, Italy, Spain, China, India and Japan
Definition, history and types of antipsychotic drugs
An understanding on receptor target of antipsychotic drugs, including dopamine, serotonin, glutamate, tachykinin and glucocorticoid
Coverage of various psychotic diseases and their indication including schizophrenia, bipolar disorder, major depressive disorder (MDD), anxiety, autism and dementia
Comprehensive company profiles of key players in the market, including Alexza Pharmaceuticals, Dr. Reddy's Laboratories, Ltd., Eli Lilly and Co., Johnson & Johnson, Teva Pharmaceutical Industries, Ltd., and Zydus Pharmaceuticals (USA), Inc.

Membership Price:

Chapter 1 Introduction

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Custom Research
Related Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Overview: Antipsychotic Drugs
History of Antipsychotic Drugs
Types of Antipsychotic Drugs
Typical Antipsychotic Drugs
Atypical Antipsychotic Drugs
Receptor Target of Antipsychotic Drugs
Dopamine
Serotonin
Glutamate
Tachykinin
Glucocorticoid
Technology Overview
Formulations
Combination Therapies

Chapter 4 Market Dynamics

Market Drivers
Rising Incidence of Mental Disorders (Schizophrenia and Bipolar Disorder)
Government and NGO Initiatives in Creating Awareness Regarding Mental Illness
Growing Geriatric Population with Mental Disorders
Increasing Prevalence of Depression and Anxiety
Market Restraints
Patent Expirations of Branded Drugs and Emergence of Generics
Adverse Side Effects Associated with Antipsychotic Drugs
Market Opportunities
Unmet Needs in Low-and Middle-Income Countries
Widening Disease Indication Areas for Antipsychotic Drugs
Loss of Patent Exclusivity: Lucrative Opportunity for Generic Manufacturers

Chapter 5 Market Breakdown by Mechanism of Action

Global Antipsychotic Drug Market
D2 Antagonists
Market Size and Forecast
Market Analysis
D2/5HT2A Antagonists
Market Size and Forecast
Market Analysis
D2 Partial Agonists
Market Size and Forecast
Market Analysis

Chapter 6 Market Breakdown by Disease Indication

Global Antipsychotic Drugs Market, by Disease Indication
Schizophrenia
Overview
Market Size and Forecast
Market Analysis
Bipolar Disorder
Overview
Market Size and Forecast
Market Analysis
Major Depressive Disorder
Overview
Market Size and Forecast
Market Analysis
Other Disease Indications
Overview
Market Size and Forecast
Market Analysis

Chapter 7 Market Breakdown by Region

Global Market for Antipsychotic Drugs, by Region
North America
United States
Canada
Mexico
Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Rest of Asia-Pacific
South America
Prevalence of Mental Illness in South America
Middle East and Africa
Prevalence of Mental Illness in the Middle East and Africa

Chapter 8 Regulatory Scenario

Regulations in the U.S.
New Drug Approval
Controlled Substances Act
The FDA Modernization Act of 1997
Fast Track Status
Special Protocol Assessments
New Surveillance and Safety Requirements
Medicare
Regulations in Europe
Pricing and Reimbursement
Regulations in Japan

Chapter 9 Patent Analysis

Patent Lengths and Market Exclusivity

Chapter 10 Pipeline Analysis

Overview of the Drug Development Process
Pipeline Analysis of Antipsychotic Drugs
Drugs in Phase I Clinical Trials
Drugs in Phase II Clinical Trials
Drugs in Phase II Clinical Trials
Late Stage Clinical Trials for Novel Drug Candidates

Chapter 11 Competitive Landscape

Global Company Share Analysis
Impact of Generic Antipsychotic Drugs on the Market

Chapter 12 Company Profiles

ACADIA PHARMACEUTICALS, INC.
Company Overview
Financials
Product Portfolio
Development and Strategies
ALEMBIC PHARMACEUTICALS, LTD.
Company Overview
Financials
Product Portfolio
Development and Strategies
ALEXZA PHARMACEUTICALS
Company Overview
Product Portfolio
Development and Strategies
ALKERMES PLC
Company Overview
Financials
Regional Revenue
Product Portfolio
Development and Strategies
ALLERGAN PLC
Company Overview
Financials
Product Portfolio
Development and Strategies
APOTEX, INC.
Company Overview
Product Portfolio
Development and Strategies
ASTRAZENECA PLC
Company Overview
Financials
AstraZeneca PLC Business Segment Revenue
AstraZeneca PLC Revenue by Region Segment
Product Portfolio
Development and Strategies
AUROBINDO PHARMA
Company Overview
Financials
Product Portfolio
Development and Strategies
DR. REDDY'S LABORATORIES LTD.
Company Overview
Financials
Product Portfolio
Development and Strategies
ELI LILLY AND CO.
Company Overview
Financials
Product Portfolio
Development and Strategies
GEDEON RICHTER PLC
Company Overview
Financials
Gedeon Richter PLC Business Segment Revenue
Gedeon Richter PLC Revenue by Region
Product Portfolio
Development and Strategies
JOHNSON & JOHNSON
Company Overview
Financials
Product Portfolio
Development and Strategies
LANNETT CO., INC.
Company Overview
Financials
Product Portfolio
Development and Strategies
H. LUNDBECK A/S
Company Overview
Financials
H. Lundbeck A/S Region Segment Revenue
Product Portfolio
Development and Strategies
LUPIN, LTD.
Company Overview
Financials
Product Portfolio
Development and Strategies
MAYNE PHARMA, INC.
Company Overview
Financials
Product Portfolio
Development and Strategies
MYLAN NV
Company Overview
Financials
Product Portfolio
Development and Strategies
OTSUKA HOLDINGS CO., LTD.
Company Overview
Financials
Otsuka Holdings Co. Ltd. Revenue by Business Segment
Otsuka Holdings Co., Ltd. Revenue by Region
Product Portfolio
Development and Strategies
SUMITOMO DAINIPPON PHARMA CO., LTD.
Company Overview
Financials
Sumitomo Dainippon Pharma Co. Ltd. Revenue by Region
Product Portfolio
Development and Strategies
SUN PHARMACEUTICAL INDUSTRIES LIMITED (SUN PHARMA)
Company Overview
Financials
Product Portfolio
Development and Strategies
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Company Overview
Financials
Product Portfolio
Development and Strategies
TORRENT PHARMACEUTICALS, LTD.
Company Overview
Financials
Product Portfolio
Development and Strategies
VANDA PHARMACEUTICALS, INC
Company Overview
Financials
Product Portfolio
Development and Strategies
WOCKHARDT
Company Overview
Financials
Product Portfolio
Development and Strategies
ZYDUS PHARMACEUTICALS (USA), INC.
Company Overview
Financials
Product Portfolio
Development and Strategies

Chapter 13 List of Abbreviations

List of Tables

Summary Table: Global Market for Antipsychotic Drugs, by Mechanism of Action, Through 2023
Table 1: Currently Approved Atypical Antipsychotics in the Market
Table 2: Administration Profile of Long-acting Atypical Antipsychotic Drugs
Table 3: Number of Bipolar Disorder Patients, by Country, 2018
Table 4: Patent Expiration Dates for Antipsychotic Drugs
Table 5: Number of Warnings About Antipsychotic Drugs
Table 6: Abilify Revenue, 2014-2017
Table 7: Indicative List of Available Generic Versions of Abilify
Table 8: Global Market for Antipsychotic Drugs, by Mechanism of Action, Through 2023
Table 9: D2 Antagonist Drugs: Market Presence
Table 10: Adverse Effects Profile of D2 Antagonist/Typical Antipsychotic Drugs
Table 11: Global Market for Antipsychotic Drugs, by Disease Indication, Through 2023
Table 12: Global Market for Antipsychotic Drugs, by Region, Through 2023
Table 13: North American Market for Antipsychotic Drugs, by Country, Through 2023
Table 14: Prevalence of Serious Mental Illness Among Adults, by State, U.S., 2017
Table 15: Prevalence of Mental Illness, by Disease Indication, U.S., 2017
Table 16: Prevalence of Mental Illness, by Disease Indication, Canada
Table 17: European Market for Antipsychotic Drugs, by Country, Through 2023
Table 18: Prevalence of Mental Illness, by Disease Indication, Germany, 2016
Table 19: Prevalence of Mental Illness, by Disease Indication, U.K., 2017
Table 20: Prevalence of Mental Illness, by Disease Indication, France, 2014
Table 21: Prevalence of Mental Illness, by Disease Indication, Italy, 2017
Table 22: Prevalence of Mental Illness, by Disease Indication, Spain, 2016
Table 23: Asia-Pacific Market for Antipsychotic Drugs, by Country, Through 2023
Table 24: Prevalence of Mental Illness, by Disease Indication, Japan, 2017
Table 25: Prevalence of Mental Illness, by Disease Indication, China, 2017
Table 26: Prevalence of Mental Illness, by Disease Indication, India, 2016
Table 27: Patent Expiration of Antipsychotic Drugs
Table 28: Exclusivity Expiration of Antipsychotic Drugs
Table 29: Phase I Pipeline of Antipsychotic Drugs
Table 30: Phase II Pipeline of Antipsychotic Drugs
Table 31: Phase III Pipeline of Antipsychotic Drugs
Table 32: Acadia Pharmaceuticals: Antipsychotic Drugs Product Portfolio
Table 33: Alembic Pharmaceuticals, Ltd.: Antipsychotic Drugs Product Portfolio
Table 34: Alexza Pharmaceuticals: Antipsychotic Drugs Product Portfolio
Table 35: Alkermes PLC: Antipsychotic Drugs Product Portfolio
Table 36: Allergan PLC: Antipsychotic Drugs Product Portfolio
Table 37: Apotex, Inc.: Antipsychotic Drugs Product Portfolio
Table 38: AstraZeneca PLC: Antipsychotic Drugs Product Portfolio
Table 39: Aurobindo Pharma: Antipsychotic Drugs Product Portfolio
Table 40: Dr. Reddy’s Laboratories, Ltd.: Antipsychotic Drugs Product Portfolio
Table 41: Eli Lilly and Co.: Products
Table 42: Gedeon Richter PLC: Antipsychotic Drugs Product Portfolio
Table 43: Johnson & Johnson: Antipsychotic Drugs Product Portfolio
Table 44: Lannett Co.: Antipsychotic Drugs Product Portfolio
Table 45: H. Lundbeck A/S: Antipsychotic Drugs Product Portfolio
Table 46: Lupin, Ltd.: Antipsychotic Drugs Product Portfolio
Table 47: Mayne Pharma, Inc.: Antipsychotic Drugs Product Portfolio
Table 48: Mylan NV: Antipsychotic Drugs Product Portfolio
Table 49: Otsuka Holdings Co., Ltd.: Antipsychotic Drugs Product Portfolio
Table 50: Sumitomo Dainippon Pharma Co., Ltd.: Antipsychotic Drugs Product Portfolio
Table 51: Sun Pharmaceuticals Industries, Ltd.: Antipsychotic Drugs Product Portfolio
Table 52: Teva Pharmaceutical Industries, Ltd.: Antipsychotic Drugs Product Portfolio
Table 53: Torrent Pharmaceuticals, Ltd.: Antipsychotic Drugs Product Portfolio
Table 54: Vanda Pharmaceuticals, Inc.: Antipsychotic Drugs Product Portfolio
Table 55: Wockhardt: Antipsychotic Drugs Product Portfolio
Table 56: Zydus Pharmaceuticals (USA), Inc.: Antipsychotic Drugs Product Portfolio
Table 57: Abbreviations Used in Antipsychotic Drugs: Technologies and Global Markets

List of Figures

Summary Figure: Global Market Share for Antipsychotic Drugs, by Mechanism of Action, 2017
Figure 1: Number of Depressive Disorder Patients, by Region, 2015
Figure 2: Number of Patients with Anxiety Disorders, by Region, 2015
Figure 3: Global Market Share for Antipsychotic Drugs, by Mechanism of Action, 2017
Figure 4: Global Market for Antipsychotic Drugs in D2 Antagonist, 2017-2023
Figure 5: Global Market for Antipsychotic Drugs in D2/5HT2A Antagonist, 2017-2023
Figure 6: Eli Lilly and Company: Sales Revenue for Zyprexa Franchise, 2014-2017
Figure 7: Johnson & Johnson: Sales Revenue for Invega, 2012-2015
Figure 8: Johnson & Johnson Sales Revenue for Invega Sustenna Franchise, 2014-2017
Figure 9: Johnson & Johnson: Sales Revenue for Risperdal Consta, 2014-2017
Figure 10: AstraZeneca: Sales Revenue for Seroquel IR, 2014-2017
Figure 11: AstraZeneca: Sales Revenue for Seroquel XR, 2014-2017
Figure 12: Sumitomo Dainippon Pharma Co. Ltd.: Sales Revenue for Latuda, 2015-2017
Figure 13: Sumitomo Dainippon Pharma Co. Ltd.: Sales Revenue for Lonasen, 2015-2017
Figure 14: Vanda Pharmaceuticals: Sales Revenue for Fanapt Franchise, 2015-2017
Figure 15: Allergan: Sales Revenue for Saphris, 2015-2017
Figure 16: Global Market for Antipsychotic Drugs in D2 Partial Agonist, 2017-2023
Figure 17: Otsuka Holdings Co. Ltd.: Sales Revenue for Abilify, 2014-2017
Figure 18: Otsuka Holdings Co. Ltd.: Sales Revenue for Abilify Maintena, 2015-2017
Figure 19: Otsuka Holdings Co. Ltd.: Sales Revenue for Rexulti, 2015-2017
Figure 20: Alkermes: Sales Revenue for Aristada, 2015-2017
Figure 21: Allergan: Sales Revenue for Vraylar, 2016 and 2017
Figure 22: Global Market Share for Antipsychotic Drugs, by Disease Indication, 2017
Figure 23: Global Market for Antipsychotic Drugs in Schizophrenia, 2017-2023
Figure 24: Global Market for Antipsychotic Drugs in Bipolar Disorder, 2017-2023
Figure 25: Global Market for Antipsychotic Drugs in Major Depressive Disorder (MDD), 2017-2023
Figure 26: Global Market for Antipsychotic Drugs in Other Disease Indications, 2017-2023
Figure 27: Global Market Share for Antipsychotic Drugs, by Region, 2017
Figure 28: North American Market Share for Antipsychotic Drugs, by Country, 2017
Figure 29: U.S. Market for Antipsychotic Drugs, 2017-2023
Figure 30: Canadian Market for Antipsychotic Drugs, 2017-2023
Figure 31: Mexican Market for Antipsychotic Drugs, 2017-2023
Figure 32: European Market Share for Antipsychotic Drugs, by Country, 2017
Figure 33: German Market for Antipsychotic Drugs, 2017-2023
Figure 34: U.K. Market for Antipsychotic Drugs, 2017-2023
Figure 35: French Market for Antipsychotic Drugs, 2017-2023
Figure 36: Italian Market for Antipsychotic Drugs, 2017-2023
Figure 37: Spanish Market for Antipsychotic Drugs, 2017-2023
Figure 38: Rest of Europe Market for Antipsychotic Drugs, 2017-2023
Figure 39: Asia-Pacific Market Share for Antipsychotic Drugs, by Country, 2017
Figure 40: Japanese Market for Antipsychotic Drugs, 2017-2023
Figure 41: Chinese Market for Antipsychotic Drugs, 2017-2023
Figure 42: Indian Market for Antipsychotic Drugs, 2017-2023
Figure 43: Rest of Asia-Pacific Market for Antipsychotic Drugs, 2017-2023
Figure 44: South American Market for Antipsychotic Drugs, 2017-2023
Figure 45: Middle East and African Market for Antipsychotic Drugs, 2017-2023
Figure 46: Global Market Share for Antipsychotic Drugs, by Manufacturer, 2017
Figure 47: Acadia Pharmaceuticals: Financial Performance, 2016 and 2017
Figure 48: Alembic Pharmaceuticals, Ltd.: Financial Performance, 2015-2017
Figure 49: Alkermes PLC: Annual Revenue, 2014-2017
Figure 50: Alkermes PLC: Revenue Share, by Region, 2017
Figure 51: Allergan PLC: Annual Revenue, 2013-2017
Figure 52: Allergan PLC: Revenue Share, by Business Unit, 2017
Figure 53: AstraZeneca PLC: Financial Performance, 2013-2017
Figure 54: AstraZeneca PLC: Revenue Share, by Business Unit, 2017
Figure 55: AstraZeneca PLC: Revenue Share, by Region, 2017
Figure 56: Aurobindo Pharma: Financial Performance, 2015-2017
Figure 57: Dr. Reddy’s Laboratories, Ltd.: Financial Performance, 2015-2017
Figure 58: Eli Lilly and Co.: Revenue, 2013-2017
Figure 59: Eli Lilly and Co.: Revenue Share, by Region, 2017
Figure 60: Eli Lilly and Co.: Revenue Share, by Business Unit, 2017
Figure 61: Gedeon Richter PLC: Financial Performance, 2014-2017
Figure 62: Gedeon Richter PLC: Revenue Share, by Business Unit, 2017
Figure 63: Gedeon Richter PLC: Revenue Share, by Region, 2017
Figure 64: Johnson & Johnson: Revenue, 2013-2017
Figure 65: Johnson & Johnson: Revenue Share, by Region, 2017
Figure 66: Johnson & Johnson: Revenue Share, by Business Unit, 2017
Figure 67: Lannett Co.: Financial Performance, 2015-2017
Figure 68: H. Lundbeck A/S: Financial Performance, 2013-2017
Figure 69: H. Lundbeck A/S: Revenue Share, by Region, 2017
Figure 70: Lupin, Ltd.: Financial Performance, 2015-2017
Figure 71: Lupin, Ltd.: Revenue Shares, by Business Segment, 2017
Figure 72: Mayne Pharma, Inc.: Financial Performance, 2015-2017
Figure 73: Mylan NV: Financial Performance, 2014-2017
Figure 74: Mylan NV: Revenue Share, by Region, 2017
Figure 75: Otsuka Holdings Co., Ltd.: Financial Performance, 2013-2017
Figure 76: Otsuka Holdings Co., Ltd.: Revenue Share, by Business Unit, 2017
Figure 77: Otsuka Holdings Co., Ltd.: Revenue Share, by Region, 2017
Figure 78: Sumitomo Dainippon Pharma Co., Ltd.: Financial Performance, 2013-2017
Figure 79: Sumitomo Dainippon Pharma Co. Ltd.: Revenue Shares, by Region, 2017
Figure 80: Sun Pharmaceuticals Industries, Ltd.: Financial Performance, 2015-2017
Figure 81: Teva Pharmaceutical Industries, Ltd.: Financial Performance, 2015-2017
Figure 82: Teva Pharmaceutical Industries, Ltd.: Revenue Share, by Region, 2017
Figure 83: Teva Pharmaceutical Industries, Ltd.: Revenue Share, by Business Segment, 2016
Figure 84: Torrent Pharmaceuticals, Ltd.: Financial Performance, 2015-2017
Figure 85: Vanda Pharmaceuticals, Inc.: Annual Revenue, 2013-2017
Figure 86: Wockhardt: Financial Performance, 2015-2017
Figure 87: Wockhardt: Revenue Share, by Region, 2017
Figure 88: Zydus Pharmaceuticals (USA), Inc.: Financial Performance, 2015-2017

Samples

LOADING...

Executive Summary

Among the mechanism of action segments, D2 partial agonists are expected to grow at the industry’s highest rate, owing to innovative drug formulations, the protection of multiple patents on the drugs and the strong product pipelines of key players. The market for D2 antagonists is anticipated to show declining growth rates due to the severe side effects associated with the drugs and the high rate of discontinuation and withdrawal of these drugs from the market.

Reasons for Doing This Study

Antipsychotic drugs were one of the largest classes of pharmaceutical drugs sold in the U.S. in 2010. A period of dynamic change in the market for antipsychotic drugs occurred during the period 2011 to 2016, when patents expired for major blockbuster drugs and the market began to experience the emergence of low-cost generic drugs. At the same time, several unique and innovative formulations of antipsychotic drugs were launched onto the market. New approaches for the treatment of psychosisrelated indications were pursued by pharmaceutical companies, as many of them looked beyond firstand second-generation antipsychotic drugs. These new antipsychotic drugs, with novel mechanisms of action or improved delivery systems, will provide powerful new alternatives for currently prescribed antipsychotic drugs.

Companies Mentioned

Acadia Pharmaceuticals, Inc.
Alembic Pharmaceuticals, Ltd.
Alexza Pharmaceuticals
Alkermes Plc
Allergan Plc
Apotex, Inc.
Astrazeneca Plc
Aurobindo Pharma
Dr. Reddy's Laboratories Ltd.
Eli Lilly and Co
Gedeon Richter Plc
H. Lundbeck A/S
Johnson & Johnson
Lannett Co., Inc.
Lupin, Ltd.
Mayne Pharma, Inc.
Mylan Nv
Otsuka Holdings Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Sun Pharmaceutical Industries Limited (Sun Pharma)
Teva Pharmaceutical Industries, Ltd
Torrent Pharmaceuticals, Ltd.
Vanda Pharmaceuticals, Inc
Wockhardt
Zydus Pharmaceuticals (USA), Inc.

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€1349EUR$1,375USD£1,122GBP €2698EUR$2,750USD£2,244GBP
1 - 5 USER LICENSE PDF	The product is a PDF.	This is a 1-5 user license, allowing up to five users have access to the product.	€1619EUR$1,650USD£1,346GBP €3238EUR$3,300USD£2,693GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€1943EUR$1,980USD£1,616GBP €3886EUR$3,960USD£3,232GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€2331EUR$2,376USD£1,939GBP €4663EUR$4,752USD£3,878GBP

Table of Contents

Samples

Executive Summary

Companies Mentioned

Related Topics

Related Reports

Antipsychotic Drugs Market by Class, Indication - Global Forecast 2025-2030

Antipsychotic Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

Antipsychotic Drugs Market - Forecasts from 2024 to 2029

Antipsychotic Drugs Market Size, Share & Trends Analysis Report By Disease (Schizophrenia, Bipolar Disorder), By Drug, By Therapeutic Class, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

Schizophrenia Drugs Market Size, Share and Trends Analysis Report by Class (Second-Generation Antipsychotics, Third-Generation Antipsychotics, Others), Treatment, Distribution Channels, and Region 2024-2030